<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value"/></p>
<p>纳斯达克 GM:ANIP 1 年股价与公允价值</p>
<p>探索 ANI 制药的社区公允价值并选择您的观点</p>
<p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) 的股票在过去一个月中继续保持其近期的势头，涨幅达 25%。回顾更长时间，令人鼓舞的是，过去一年该股上涨了 41%。</p>
<p>即使在如此大幅的价格上涨之后，考虑到美国制药行业几乎一半的公司市销率（&#34;P/S&#34;）超过 5.8 倍，甚至市销率超过 18 倍的情况也并不罕见，ANI 制药目前仍可能被视为一个强劲的买入机会，其市销率为 2.2 倍。然而，我们需要更深入地挖掘，以确定这种大幅降低的市销率是否有合理的基础。</p>
<p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>查看我们对 ANI 制药的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616"/></p>
<p>纳斯达克 GM:ANIP 市销率与行业比较 2025 年 8 月 10 日</p>
<h3>ANI 制药的表现如何</h3>
<p>ANI 制药最近的表现确实不错，其收入增长超过了大多数其他公司。一个可能性是，市销率之所以较低，是因为投资者认为这种强劲的收入表现未来可能不那么令人印象深刻。如果您喜欢这家公司，您会希望情况不是这样，以便您可以在其不受欢迎时购买一些股票。</p>
<p>如果您想了解分析师对未来的预测，您应该查看我们对 ANI 制药的 <strong>免费</strong> 报告。</p>
<h2>ANI 制药是否有收入增长的预测？</h2>
<p>您唯一会真正感到舒适的情况是，当公司的增长明显落后于行业时，才会看到像 ANI 制药这样低迷的市销率。</p>
<p>如果我们回顾过去一年的收入增长，该公司实现了 39% 的可喜增长。强劲的近期表现意味着它在过去三年中总共实现了 197% 的收入增长。因此，我们可以首先确认该公司在这段时间内在收入增长方面做得很好。</p>
<p>展望未来，根据跟踪该公司的八位分析师的预测，预计收入将在未来三年内每年增长 8.9%。与此同时，行业的其余部分预计每年将增长 26%，这显然更具吸引力。</p>
<p>根据这些信息，我们可以看到为什么 ANI 制药的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
<h2>最终结论</h2>
<p>ANI 制药最近的股价上涨仍未使其市销率与行业中位数相匹配。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>我们已经确定，ANI 制药维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非这些条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
<p>在您采取下一步之前，您应该了解我们发现的 <strong>ANI 制药的 1 个警告信号</strong>。</p>
<p>如果您对盈利的强劲公司感兴趣，那么您会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司交易的市盈率较低（但已证明它们能够增长收益）。</p>

ANI制药

<p>ANI 制药公司（NASDAQ:ANIP）在过去一个月的股价上涨了 25%，在过去一年中上涨了 41%。尽管如此，该公司的市销率（P/S）仍然较低，为 2.2 倍，而行业平均水平为 5.8 倍。分析师预测未来三年年均收入增长为 8.9%，远低于行业的 26%。这种增长预期的差异导致了低市销率，表明投资者对未来表现的怀疑。如果增长预期没有改善，股价可能会保持受限</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/6DB65A5B-AE16-4085-BB3C-77EED6BDDE9D/chart/price-vs-fair-value"/></p>
<p>NasdaqGM:ANIP 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>纳斯达克 GM:ANIP 1 年股价与公允价值</p>
</div><p>Explore ANI Pharmaceuticals's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索 ANI 制药的社区公允价值并选择您的观点</p>
</div><p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a bit further, it's encouraging to see the stock is up 41% in the last year.</p>
<div class="lb-trans"><p><strong>ANI Pharmaceuticals, Inc.</strong> (NASDAQ:ANIP) 的股票在过去一个月中继续保持其近期的势头，涨幅达 25%。回顾更长时间，令人鼓舞的是，过去一年该股上涨了 41%。</p>
</div><p>Even after such a large jump in price, ANI Pharmaceuticals may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 2.2x, considering almost half of all companies in the Pharmaceuticals industry in the United States have P/S ratios greater than 5.8x and even P/S higher than 18x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的价格上涨之后，考虑到美国制药行业几乎一半的公司市销率（&#34;P/S&#34;）超过 5.8 倍，甚至市销率超过 18 倍的情况也并不罕见，ANI 制药目前仍可能被视为一个强劲的买入机会，其市销率为 2.2 倍。然而，我们需要更深入地挖掘，以确定这种大幅降低的市销率是否有合理的基础。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要&#34;释放&#34;美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>Check out our latest analysis for ANI Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 ANI 制药的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616" alt="" original-src="https://images.simplywall.st/asset/chart/1528824-ps-multiple-vs-industry-1-dark-2/1754836260616"/></p>
<p>NasdaqGM:ANIP Price to Sales Ratio vs Industry August 10th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:ANIP 市销率与行业比较 2025 年 8 月 10 日</p>
</div><h3>How ANI Pharmaceuticals Has Been Performing</h3>
<div class="lb-trans"><h3>ANI 制药的表现如何</h3>
</div><p>ANI Pharmaceuticals certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>ANI 制药最近的表现确实不错，其收入增长超过了大多数其他公司。一个可能性是，市销率之所以较低，是因为投资者认为这种强劲的收入表现未来可能不那么令人印象深刻。如果您喜欢这家公司，您会希望情况不是这样，以便您可以在其不受欢迎时购买一些股票。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on ANI Pharmaceuticals.</p>
<div class="lb-trans"><p>如果您想了解分析师对未来的预测，您应该查看我们对 ANI 制药的 <strong>免费</strong> 报告。</p>
</div><h2>Is There Any Revenue Growth Forecasted For ANI Pharmaceuticals?</h2>
<div class="lb-trans"><h2>ANI 制药是否有收入增长的预测？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as ANI Pharmaceuticals' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>您唯一会真正感到舒适的情况是，当公司的增长明显落后于行业时，才会看到像 ANI 制药这样低迷的市销率。</p>
</div><p>If we review the last year of revenue growth, the company posted a terrific increase of 39%. The strong recent performance means it was also able to grow revenue by 197% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>如果我们回顾过去一年的收入增长，该公司实现了 39% 的可喜增长。强劲的近期表现意味着它在过去三年中总共实现了 197% 的收入增长。因此，我们可以首先确认该公司在这段时间内在收入增长方面做得很好。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 8.9% per annum during the coming three years according to the eight analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 26% per annum, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未来，根据跟踪该公司的八位分析师的预测，预计收入将在未来三年内每年增长 8.9%。与此同时，行业的其余部分预计每年将增长 26%，这显然更具吸引力。</p>
</div><p>With this information, we can see why ANI Pharmaceuticals is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>根据这些信息，我们可以看到为什么 ANI 制药的市销率低于行业水平。似乎大多数投资者预计未来增长有限，因此只愿意为该股票支付较低的价格。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最终结论</h2>
</div><p>ANI Pharmaceuticals' recent share price jump still sees fails to bring its P/S alongside the industry median. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>ANI 制药最近的股价上涨仍未使其市销率与行业中位数相匹配。我们认为市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>We've established that ANI Pharmaceuticals maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>我们已经确定，ANI 制药维持其低市销率是因为其预测增长低于更广泛的行业，正如预期的那样。在这个阶段，投资者认为收入改善的潜力不足以证明更高的市销率。除非这些条件改善，否则它们将继续在这些水平上形成股价的障碍。</p>
</div><p>Before you take the next step, you should know about the <strong>1 warning sign for ANI Pharmaceuticals</strong> that we have uncovered.</p>
<div class="lb-trans"><p>在您采取下一步之前，您应该了解我们发现的 <strong>ANI 制药的 1 个警告信号</strong>。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果您对盈利的强劲公司感兴趣，那么您会想查看这份 <strong>免费</strong> 的有趣公司名单，这些公司交易的市盈率较低（但已证明它们能够增长收益）。</p>
</div>

ANI 制药公司（NASDAQ:ANIP）股价飙升 25%，但其低市销率并不足以令人感到兴奋